Who We Are

KELIX bio is a specialty generic business focused on Emerging Markets and designed to compete through innovation and cost leadership. KELIX bio aims to develop and commercialize affordable specialty products in jurisdictions historically deprived of access to such medications. KELIX bio’s investors include Development Partners International (“DPI”), British International Investment (“BII”), the UK’s publicly owned impact investor, and the European Bank for Reconstruction and Development (“EBRD”).